Tag - Astrocyte Pharmaceuticals

Astrocyte Pharmaceuticals Awarded Major Grant to Further Develop Promising Treatment for Brain Injury

Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, announced today that it has received a $500,000 award jointly funded by the Medical Technology Enterprise Consortium (MTEC) and the BrightFocus Foundation. Read more >>

Neuroprotection Drugs Market is Expected to Reach US$ 33,481.7 Million by 2027 with major key players

Rising usage of atypical antipsychotics, omega‐3 fatty acids, antidepressants, glutamateric neurotransmission modulators, erythropoietin, COX‐2 inhibitors and N‐acetylcysteine have anti‐apoptotic properties which can help in brain maturational processes from psychotic disorders. Clinical trial processes suggested that these category of drugs help in preventing the onset of frank psychosis. A company named, Astrocyte Pharmaceuticals Inc., which is a drug development company is engaged in providing advanced breakthroughs in neuroprotection drugs market to repair neurons that are caused due to brain injury. […]

StartUPDATES: New developments from healthcare startups

Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for treating neurodegenerative brain injuries, has completed a Series A funding round that raised $6 million. The company’s lead therapeutic is based on technology originally licensed from University of Texas Health Science Center at San Antonio, to address the unmet need for a drug that can reduce injury to the brain resulting from stroke, traumatic brain injury, concussion and other neurodegenerative conditions. Read more >>

Astrocyte Pharmaceuticals Raises $6M Series A to Advance Next Generation Stroke and TBI Treatment to the Clinic

Groton, CT, May 3, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries, announced today the completion of the Company’s Series A financing that raised $6.0M. Astrocyte is progressing its lead development candidate AST-004, based upon technology originally licensed from The University of Texas Health Science Center at San Antonio, to address the unmet need for a drug that can reduce injury to the brain resulting from stroke, […]

Groton Connecticut based Astrocyte Pharmaceuticals is raising $8,655,148.00 in New Equity Investment.

According to filings with the U.S. Securities and Exchange Commission, Astrocyte Pharmaceuticals is raising $8,655,148.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, William Korinek played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development. Read more >>

The search for a pill that treats concussions

William Korinek loves professional football and, as a native Minnesotan who moved to New England in 1995, he roots for both the Patriots and the Vikings. But he won’t let his 11-year-old son, Jonah, play tackle football.
“It’s too risky,” said the 45-year-old molecular biologist.
Korinek is cofounder and chief executive of Astrocyte Pharmaceuticals, a Cambridge startup trying to develop a drug to treat concussions. Read more >>

Boston Harbor Angels Awards Portfolio Companies at Annual Meeting

Boston Harbor Angels, one of the top three elite angels groups in the US, recognized three portfolio companies at its annual end-of-year general meeting.
Exit of the Year Award: Corbus Pharmaceuticals on NASDAQ
Biotech Startup of the Year Award: Astrocytes Pharmaceuticals Inc.
IT Startup of the Year Award: Wasabi
The meeting featured interviews with Yuval Cohen, CEO of Corbus Pharmaceuticals and Mark Tepper, President & Chief Scientific Officer of Corbus Pharmaceuticals; and David Friend, CEO and co-founder of Wasabi.
The group also honored Mic […]

NFL’s New Concussion Pill Could Be Filled With CBD

Although the search for a concussion pill is merely in the “mouse model” phase, significant strides have been made by researchers. Dr. William Korinek, the CEO of Astrocyte Pharmaceuticals, believes such a pill can arrive as early as 2025. Dr. Kun Ping Lu, a doctor researching a possible medication to destroy compounds that cause brain damage, has a slightly-less optimistic time frame. He believes a possible pill could arrive within the next ten years. Read more >>